Organisation paid for research Program year 2025 Source: CMS Open Payments

Solutions Through Advanced Research Inc

Neither a doctor nor a teaching hospital

Research payments

$859,363

534 payments

Through program year 2025, Solutions Through Advanced Research Inc is reported as receiving $859,363 in research payments, across 534 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$20,560	10
2024	Research	$57,428	295
2023	Research	$54,511	133
2022	Research	$37,024	18
2021	Research	$360,531	11
2020	Research	$271,079	50
2019	Research	$58,231	17

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $547,021 29 payments
Pfizer Inc. $120,441 45 payments
Dermavant Sciences, Inc. $105,852 429 payments
Regeneron Pharmaceuticals, Inc. $18,365 2 payments
AbbVie, Inc. $17,502 14 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $17,123 2 payments
Ucb SA $12,386 2 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $10,265 4 payments
VYNE Pharmaceuticals Inc. $6,325 1 payment
GlaxoSmithKline, LLC. $3,571 4 payments

Studies the money was for Research payments · program years 2019–2025

PPSO-004/20200057 (SPROUT Rollover) $249,223 2 payments
Efficacy/Safety Study of Apremilast in Pedi Subjects With Moderate to Severe Plaque PSO (PPSO-003) $159,686 21 payments
Ppso-003/20200056 (Sprout) $103,418 2 payments
An Openlabel Extension Study to Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis $37,053 12 payments
Open Label Extension study for PPSO-003 (PPSO-004) $34,542 2 payments
An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $33,995 34 payments
An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $32,810 230 payments
A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children With Adults $29,681 109 payments
Phase 2AB Safety and Efficacy Study of Pf06700841 in Atopic Dermatitis Patients $28,896 12 payments
52 wks Eff. & Saf. Ph III in Paediatrics $27,902 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.